nach oben

Current Treatment Options in Neurology

Erschienen in:

01.11.2010 | Pediatric Neurology

Newer Anticonvulsant Medications in Pediatric Neurology

verfasst von: Michael M. Quach, MD, Abdul Mazin, MD, James J. Riviello Jr, MD

Erschienen in: Current Treatment Options in Neurology | Ausgabe 6/2010

Einloggen, um Zugang zu erhalten

Opinion statement

Antiepileptic drugs (AEDs) are the mainstay of treatment for recurrent seizures. Uncontrolled seizures may cause medical, developmental, and psychological disturbances. The medical practitioner should thus strive to eliminate or minimize seizures. Treatment advances in epilepsy include 1) identification of the basic mechanisms of epilepsy and action of AEDs, 2) the introduction of new AEDs, and 3) the use of neurostimulation, including vagus nerve stimulation. Treatment with AEDs involves balancing each AED’s efficacy against its side effects. In some patients, effective AEDs must be discontinued because of intolerable side effects. Although all AEDs have a proven efficacy, the choice of AEDs should be based on better efficacy for individual seizure types or epilepsy syndromes. Side effects also differ from drug to drug and must be taken into account. This article focuses on studies and expert opinion consensus to guide the choice of AEDs.

Abdul M, Riviello JJ: Update on the newer antiepileptic drugs in child neurology: advances in treatment of pediatric epilepsy. Curr Treat Options Neurol 2007, 9:395–403.CrossRefPubMed

Malphrus AD, Wilfong AA: Use of the newer antiepileptic drugs in pediatric epilepsies. Curr Treat Options Neurol 2007, 9:256–267.CrossRefPubMed

French JA, Kanner AM, Bautista J, et al.: Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy. Neurology 2004, 62:1252–1260.PubMed

4.••

Chung AM, Eiland LS: Use of second-generation antiepileptic drugs in the pediatric population. Paediatr Drugs 2008, 10:217–254. This is a very comprehensive, in-depth review of the newer antiepileptic drugs.

5.••

Depositario-Cabacar DT, Peters JM, Pong AW, et al.: High-dose intravenous levetiracetam for acute seizure exacerbation in children with intractable epilepsy. Epilepsia 2010, 51:1319–1322. This is an excellent retrospective study on high-dose levetiracetam in children.

Zupanc ML: Roell Werner R, Schwabe MS, et al.: Efficacy of felbamate in the treatment of intractable pediatric epilepsy. Pediatr Neurol 2010, 42:396–403.CrossRefPubMed

Hwang H, Kim KJ: New antiepileptic drugs in pediatric epilepsy. Brain Dev 2008, 30:549–555.CrossRefPubMed

Grosso S, Cordelli DM, Coppola G, et al.: Efficacy and safety of felbamate in children under 4 years of age: a retrospective chart review. Eur J Neurol 2008, 15:940–946.CrossRefPubMed

Cilio MR, Kartashov AI, Vigevano F: The long-term use of felbamate in children with severe refractory epilepsy. Epilepsy Res 2001, 47:1–7.CrossRefPubMed

10.

Pellock JM: New pharmacotherapies for pediatric seizures. Pediatr Ann 2004, 33:385–391.PubMed

11.

Prasad AN, Penney S, Buckley DJ: The role of vigabatrin in childhood seizure disorders: results from a clinical audit. Epilepsia 2001, 42:54–61.CrossRefPubMed

12.

Kossoff EH: Infantile spasms. Neurologist 2010, 16:69–75.CrossRefPubMed

13.

Elterman RD, Shields WD, Mansfield KA, et al.: Randomized trial of vigabatrin in patients with infantile spasms. Neurology 2001, 57:1416–1421.PubMed

14.•

Piña-Garza JE, Levisohn P, Gucuyener K, et al.: Adjunctive lamotrigine for partial seizures in patients aged 1 to 24 months. Neurology 2008, 70:2099–2108. This article does a good job of examining the safety and efficacy of lamotrigine in very young patients.

15.

Mikati MA, Fayad M, Koleilat M, et al.: Efficacy, tolerability, and kinetics of lamotrigine in infants. J Pediatr 2002, 141:31–35.CrossRefPubMed

16.

Barron TF, Hunt SL, Hoban TF, et al.: Lamotrigine monotherapy in children. Pediatr Neurol 2000, 23:160–163.CrossRefPubMed

17.

Błaszczyk B, Czuczwar SJ: Efficacy, safety, and potential of extended-release lamotrigine in the treatment of epileptic patients. Neuropsychiatr Dis Treat 2010, 6:145–150.PubMed

18.

Thomé-Souza S, Freitas A, Fiore LA, et al.: Lamotrigine and valproate: efficacy of co-administration in a pediatric population. Pediatr Neurol 2003, 28:360–364.CrossRefPubMed

19.

Bourgeois BF: Pharmacokinetics and pharmacodynamics of topiramate. J Child Neurol 2000, 15(Suppl 1):S27–S30.CrossRefPubMed

20.

Kwon YS, Jun YH, Hong YJ, et al.: Topiramate monotherapy in infantile spasm. Yonsei Med J 2006, 47:498–504.CrossRefPubMed

21.

Glauser TA, Clark PO, McGee K: Long-term response to topiramate in patients with West syndrome. Epilepsia 2000, 41(Suppl 1):S91–S94.CrossRefPubMed

22.

Kim SC, Seol IJ, Kim SJ: Hypohidrosis-related symptoms in pediatric epileptic patients with topiramate. Pediatr Int 2010, 52:109–112.CrossRefPubMed

23.

Blumkin L, Lerman-Sagie T, Houri T, et al.: Pediatric refractory partial status epilepticus responsive to topiramate. J Child Neurol 2005, 20:239–241.PubMed

24.

Watemberg N, Goldberg-Stern H, Ben-Zeev B, et al.: Clinical experience with open-label topiramate use in infants younger than 2 years of age. J Child Neurol 2003, 18:258–262.CrossRefPubMed

25.

Perry MS, Holt PJ, Sladky JT: Topiramate loading for refractory status epilepticus in children. Epilepsia 2006, 47:1070–1071.CrossRefPubMed

26.

Mangano S, Cusumano L, Fontana A: Non-convulsive status epilepticus associated with tiagabine in a pediatric patient. Brain Dev 2003, 25:518–521.CrossRefPubMed

27.

Vigevano F: Levetiracetam in pediatrics. J Child Neurol 2005, 20:87–93.CrossRefPubMed

28.

Goraya JS, Khurana DS, Valencia I, et al.: Intravenous levetiracetam in children with epilepsy. Pediatr Neurol 2008, 38:177–180.CrossRefPubMed

29.

Pellock JM, Glauser TA, Bebin EM, et al.: Pharmacokinetic study of levetiracetam in children. Epilepsia 2001, 42:1574–1579.CrossRefPubMed

30.

Mandelbaum DE, Bunch M, Kugler SL, et al.: Efficacy of levetiracetam at 12 months in children classified by seizure type, cognitive status, and previous anticonvulsant drug use. J Child Neurol 2005, 20:590–594.PubMed

31.

Abend NS, Florance N, Finkel RS, et al.: Intravenous levetiracetam terminates refractory focal status epilepticus. Neurocrit Care 2009, 10:83–86.CrossRefPubMed

32.

Gallentine WB, Hunnicutt AS, Husain AM: Levetiracetam in children with refractory status epilepticus. Epilepsy Behav 2009, 14:215–218.CrossRefPubMed

33.

Davis GP, McCarthy JT, Magill DB, et al.: Behavioral effects of levetiracetam mitigated by pyridoxine. J Child Adolesc Psychopharmacol 2009, 19:209–211.CrossRefPubMed

34.

Kothare SV, Mostofi N, Khurana DS, et al.: Oxcarbazepine therapy in very young children: a single-center clinical experience. Pediatr Neurol 2006, 35:173–176.CrossRefPubMed

35.

Piña-Garza JE, Espinoza R, Nordli D, et al.: Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology 2005, 65:1370–1375.CrossRefPubMed

36.

Wilfong AA, Willmore LJ: Zonisamide—a review of experience and use in partial seizures. Neuropsychiatr Dis Treat 2006, 2:269–280.CrossRefPubMed

37.

Wilfong A, Schultz R: Zonisamide for absence seizures. Epilepsy Res 2005, 64:31–34.CrossRefPubMed

38.

Wheless JW, Conry J, Krauss G, et al.: Safety and tolerability of rufinamide in children with epilepsy: a pooled analysis of 7 clinical studies. J Child Neurol 2009, 24:1520–1525.CrossRefPubMed

39.

Kluger G, Kurlemann G, Haberlandt E, et al.: Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience. Epilepsy Behav 2009, 14:491–495.CrossRefPubMed

40.

Kluger G, Haberlandt E, Kurlemann G, et al.: First European long-term experience with the orphan drug rufinamide in childhood-onset refractory epilepsy. Epilepsy Behav 2010, 17:546–548.CrossRefPubMed

41.

Kluger G, Bauer B: Role of rufinamide in the management of Lennox-Gastaut syndrome (childhood epileptic encephalopathy). Neuropsychiatr Dis Treat 2007, 3:3–11.CrossRefPubMed

42.

Glauser T, Kluger G, Sachdeo R, et al.: Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology 2008, 70:1950–1958.CrossRefPubMed

43.

Kellinghaus C, Berning S, Besselmann M: Intravenous lacosamide as successful treatment for nonconvulsive status epilepticus after failure of first-line therapy. Epilepsy Behav 2009, 14:429–431.CrossRefPubMed

44.

Tilz C, Resch R, Hofer T, et al.: Successful treatment for refractory convulsive status epilepticus by non-parenteral lacosamide. Epilepsia 2010, 51:316–317.CrossRefPubMed

45.

Errington AC, Stöhr T, Heers C, Lees G: The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 2008, 73:157–169.CrossRefPubMed

46.

Halász P, Kälviäinen R, Mazurkiewicz-Beldzińska M, et al.: Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial. Epilepsia 2009, 50:443–453.CrossRefPubMed

47.

Curia G, Biagini G, Perucca E, et al.: Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs 2009, 23:555–568.CrossRefPubMed

48.

Abou-Khalil BW: Lacosamide: what can be expected from the next new antiepileptic drug? Epilepsy Curr 2009, 9:133–134.CrossRefPubMed

49.

Chung S, Sperling MR, Biton V, et al.: Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia 2010, 51:958–967.CrossRefPubMed

50.

Krauss G, Ben-Menachem E, Mameniskiene R, et al.: Intravenous lacosamide as short-term replacement for oral lacosamide in partial-onset seizures. Epilepsia 2009, 51:951–957.CrossRefPubMed

51.

Wheless JW, Clarke DF, Carpenter D: Treatment of pediatric epilepsy: expert opinion, 2005. J Child Neurol 2005, 20(Suppl 1):S1–S56.PubMed

52.••

Glauser TA, Cnaan A, Shinnar S, et al.: Ethosuximide, valproic acid, and lamotrigine for childhood absence epilepsy. N Engl J Med 2010, 362:790–799. This landmark multicenter, double-blind randomized clinical trial, sponsored by the NIH, examined the efficacy and tolerability of ethosuximide, valproate, and lamotrigine in treating childhood absence epilepsy.

Titel: Newer Anticonvulsant Medications in Pediatric Neurology
verfasst von: Michael M. Quach, MD
Abdul Mazin, MD
James J. Riviello Jr, MD
Publikationsdatum: 01.11.2010
Verlag: Current Science Inc.
Erschienen in: Current Treatment Options in Neurology / Ausgabe 6/2010
Print ISSN: 1092-8480
Elektronische ISSN: 1534-3138
DOI: https://doi.org/10.1007/s11940-010-0094-5

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

25.04.2024 | Hypotonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Newer Anticonvulsant Medications in Pediatric Neurology

Opinion statement

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie

Springer Medizin

Opinion statement

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2010

Diabetes Mellitus, Acute Hyperglycemia, and Ischemic Stroke

Management of Patent Foramen Ovale and Stroke

Acute Treatment of Hypertensive Intracerebral Hemorrhage

Management of Stenosis of the Extracranial Internal Carotid Artery: Endarterectomy Versus Angioplasty and Stenting

Treatment of Tics and Tourette Syndrome

Pharmacologic Treatment of Behavioral Symptoms Associated With Autism and Other Pervasive Developmental Disorders

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie